Page last updated: 2024-09-04

vatalanib and Leucocythaemia

vatalanib has been researched along with Leucocythaemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bloomfield, CD; Gupta, P; Hasserjian, RP; Hurd, DD; Larson, RA; Mulkey, F; Odenike, OM; Owzar, K; Sanford, BL; Stone, RM; Vij, R	1

Trials

1 trial(s) available for vatalanib and Leucocythaemia

Article	Year
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Investigational new drugs, 2013, Volume: 31, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome	2013

Article

Year

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).

Investigational new drugs, 2013, Volume: 31, Issue:5

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome

2013